Q2 Earnings Estimate for Celcuity Issued By Leerink Partnrs

Celcuity Inc. (NASDAQ:CELC - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Celcuity in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.85) per share for the quarter. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share.

CELC has been the subject of several other reports. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th. Needham & Company LLC increased their price target on Celcuity from $23.00 to $29.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $30.17.

Celcuity Price Performance

Celcuity stock traded up $0.23 during trading hours on Friday, hitting $12.10. 198,357 shares of the company traded hands, compared to its average volume of 238,602. Celcuity has a 1-year low of $10.35 and a 1-year high of $22.19. The firm has a market cap of $449.27 million, a P/E ratio of -4.64 and a beta of 0.73. The firm's 50-day simple moving average is $12.28 and its two-hundred day simple moving average is $14.29. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65.

Institutional Investors Weigh In On Celcuity

Several large investors have recently modified their holdings of CELC. Acuta Capital Partners LLC raised its position in shares of Celcuity by 3.6% during the third quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company's stock worth $695,000 after purchasing an additional 1,600 shares during the period. Corebridge Financial Inc. boosted its holdings in shares of Celcuity by 12.9% in the fourth quarter. Corebridge Financial Inc. now owns 16,256 shares of the company's stock worth $213,000 after buying an additional 1,858 shares during the period. nVerses Capital LLC acquired a new position in shares of Celcuity in the third quarter worth about $33,000. Prospera Private Wealth LLC purchased a new position in shares of Celcuity in the third quarter worth approximately $35,000. Finally, New York State Common Retirement Fund raised its holdings in shares of Celcuity by 14.9% during the fourth quarter. New York State Common Retirement Fund now owns 28,391 shares of the company's stock valued at $372,000 after acquiring an additional 3,682 shares during the period. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.